Last reviewed · How we verify

NCT05812638

Mental Imagery for Lower Limb Functions

Status unknown NA Last updated 13 April 2023
What this trial tests

NA trial testing Mental imagery technique in Stroke in 28 participants. Status unknown.

Timeline
1 March 2023
Primary endpoint
30 September 2023
30 September 2023

Quick facts

Lead sponsorRiphah International University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment28
Start date1 March 2023
Primary completion30 September 2023
Estimated completion30 September 2023
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Riphah International University

Who can join

Adults 40 to 60, any sex, with Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Stroke is a neurological impairment occurs due to cardiovascular abnormality and cerebrovascular disease. The term 'stroke' is mostly used when there is sudden loss of function of the body due any abrupt changes.The rates of disability are increasing along with mortality and morbidity rates due to stroke. The poor motor performance of lower limb affects gait severely. The slow velocity and other gait deviations limit the stroke survivors' ability to perform ADL's and interfere with their quality of life. Hence, rehabilitation is obligatory for these patients to improve their quality of life

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Riphah International University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05812638.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing